Silo Pharma, Inc. — Form 8-K
Filed August 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Silo Pharma acquired web-based software called 'Reputation Endpoints' from Parkview Consulting LLC on August 18, 2026, paying 165,000 shares of common stock (par value $0.0001/share). Parkview transferred all source code, object code, intellectual property, and related materials. The shares are subject to a 12-month lockup period. Parkview warranted the software is original, contains no malicious code, and does not infringe third-party rights.
Why this rating
For a $5.3M company, acquiring a software asset is material. 165K shares represents dilution; valuing at recent market prices (~$0.032/share if typical micro-cap), this is ~$5.3K consideration—modest in dollar terms but strategically significant if Reputation Endpoints generates meaningful revenue or is core to product offering. Positive assuming asset quality; risk if software underperforms or IP claims emerge post-acquisition.
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.